Distinct impact of three different statins on arteriovenous fistula outcomes: A retrospective analysis

Laisel Martinez, Juan C. Duque, Luis A. Escobar, Marwan Tabbara, Arif Asif, Fadi Fayad, Roberto I Vazquez-Padron, Loay Salman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Whether statins improve arteriovenous fistula (AVF) outcomes is still a matter of debate. Taking into consideration the existing physicochemical differences between individual drugs, this study evaluates the impact of three different statins (atorvastatin, rosuvastatin and simvastatin) on one-stage and two-stage AVF outcomes. Methods: Using a retrospective cohort of 535 patients, we analyzed the effects of each statin on primary failure and primary patency using multivariate logistic regressions and Cox proportional hazard models. Results: Out of the three statins analyzed, only atorvastatin improved the overall primary failure of AVF (odds ratio [OR] = 0.18, p = 0.005). Comparisons between the two AVF types demonstrated that this effect was due to a prominent reduction in primary failure of one-stage (OR = 0.03; p = 0.005), but not two-stage fistulas (OR = 0.43; p = 0.25). In contrast, primary patency of two-stage (hazards ratio [HR] = 0.51; p = 0.024), but not one-stage fistulas (HR = 0.98; p = 0.95), was improved by all statins as a group, but not by individual drugs. Conclusions: Our results suggest that the potential benefit of statins on AVF outcomes is a drug-specific and not a class effect, and that such effect is also influenced by the type of fistula.

Original languageEnglish (US)
Pages (from-to)471-476
Number of pages6
JournalJournal of Vascular Access
Volume17
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Arteriovenous Fistula
Fistula
Odds Ratio
Pharmaceutical Preparations
Simvastatin
Proportional Hazards Models
Individuality
Logistic Models

Keywords

  • Arteriovenous fistula
  • Atorvastatin
  • Primary failure
  • Rosuvastatin
  • Simvastatin
  • Statin

ASJC Scopus subject areas

  • Surgery
  • Nephrology

Cite this

Distinct impact of three different statins on arteriovenous fistula outcomes : A retrospective analysis. / Martinez, Laisel; Duque, Juan C.; Escobar, Luis A.; Tabbara, Marwan; Asif, Arif; Fayad, Fadi; Vazquez-Padron, Roberto I; Salman, Loay.

In: Journal of Vascular Access, Vol. 17, No. 6, 01.11.2016, p. 471-476.

Research output: Contribution to journalArticle

Martinez, Laisel ; Duque, Juan C. ; Escobar, Luis A. ; Tabbara, Marwan ; Asif, Arif ; Fayad, Fadi ; Vazquez-Padron, Roberto I ; Salman, Loay. / Distinct impact of three different statins on arteriovenous fistula outcomes : A retrospective analysis. In: Journal of Vascular Access. 2016 ; Vol. 17, No. 6. pp. 471-476.
@article{fb5f787a480f4328b6020cfcc5fe24db,
title = "Distinct impact of three different statins on arteriovenous fistula outcomes: A retrospective analysis",
abstract = "Purpose: Whether statins improve arteriovenous fistula (AVF) outcomes is still a matter of debate. Taking into consideration the existing physicochemical differences between individual drugs, this study evaluates the impact of three different statins (atorvastatin, rosuvastatin and simvastatin) on one-stage and two-stage AVF outcomes. Methods: Using a retrospective cohort of 535 patients, we analyzed the effects of each statin on primary failure and primary patency using multivariate logistic regressions and Cox proportional hazard models. Results: Out of the three statins analyzed, only atorvastatin improved the overall primary failure of AVF (odds ratio [OR] = 0.18, p = 0.005). Comparisons between the two AVF types demonstrated that this effect was due to a prominent reduction in primary failure of one-stage (OR = 0.03; p = 0.005), but not two-stage fistulas (OR = 0.43; p = 0.25). In contrast, primary patency of two-stage (hazards ratio [HR] = 0.51; p = 0.024), but not one-stage fistulas (HR = 0.98; p = 0.95), was improved by all statins as a group, but not by individual drugs. Conclusions: Our results suggest that the potential benefit of statins on AVF outcomes is a drug-specific and not a class effect, and that such effect is also influenced by the type of fistula.",
keywords = "Arteriovenous fistula, Atorvastatin, Primary failure, Rosuvastatin, Simvastatin, Statin",
author = "Laisel Martinez and Duque, {Juan C.} and Escobar, {Luis A.} and Marwan Tabbara and Arif Asif and Fadi Fayad and Vazquez-Padron, {Roberto I} and Loay Salman",
year = "2016",
month = "11",
day = "1",
doi = "10.5301/jva.5000612",
language = "English (US)",
volume = "17",
pages = "471--476",
journal = "Journal of Vascular Access",
issn = "1129-7298",
publisher = "Wichtig Publishing",
number = "6",

}

TY - JOUR

T1 - Distinct impact of three different statins on arteriovenous fistula outcomes

T2 - A retrospective analysis

AU - Martinez, Laisel

AU - Duque, Juan C.

AU - Escobar, Luis A.

AU - Tabbara, Marwan

AU - Asif, Arif

AU - Fayad, Fadi

AU - Vazquez-Padron, Roberto I

AU - Salman, Loay

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose: Whether statins improve arteriovenous fistula (AVF) outcomes is still a matter of debate. Taking into consideration the existing physicochemical differences between individual drugs, this study evaluates the impact of three different statins (atorvastatin, rosuvastatin and simvastatin) on one-stage and two-stage AVF outcomes. Methods: Using a retrospective cohort of 535 patients, we analyzed the effects of each statin on primary failure and primary patency using multivariate logistic regressions and Cox proportional hazard models. Results: Out of the three statins analyzed, only atorvastatin improved the overall primary failure of AVF (odds ratio [OR] = 0.18, p = 0.005). Comparisons between the two AVF types demonstrated that this effect was due to a prominent reduction in primary failure of one-stage (OR = 0.03; p = 0.005), but not two-stage fistulas (OR = 0.43; p = 0.25). In contrast, primary patency of two-stage (hazards ratio [HR] = 0.51; p = 0.024), but not one-stage fistulas (HR = 0.98; p = 0.95), was improved by all statins as a group, but not by individual drugs. Conclusions: Our results suggest that the potential benefit of statins on AVF outcomes is a drug-specific and not a class effect, and that such effect is also influenced by the type of fistula.

AB - Purpose: Whether statins improve arteriovenous fistula (AVF) outcomes is still a matter of debate. Taking into consideration the existing physicochemical differences between individual drugs, this study evaluates the impact of three different statins (atorvastatin, rosuvastatin and simvastatin) on one-stage and two-stage AVF outcomes. Methods: Using a retrospective cohort of 535 patients, we analyzed the effects of each statin on primary failure and primary patency using multivariate logistic regressions and Cox proportional hazard models. Results: Out of the three statins analyzed, only atorvastatin improved the overall primary failure of AVF (odds ratio [OR] = 0.18, p = 0.005). Comparisons between the two AVF types demonstrated that this effect was due to a prominent reduction in primary failure of one-stage (OR = 0.03; p = 0.005), but not two-stage fistulas (OR = 0.43; p = 0.25). In contrast, primary patency of two-stage (hazards ratio [HR] = 0.51; p = 0.024), but not one-stage fistulas (HR = 0.98; p = 0.95), was improved by all statins as a group, but not by individual drugs. Conclusions: Our results suggest that the potential benefit of statins on AVF outcomes is a drug-specific and not a class effect, and that such effect is also influenced by the type of fistula.

KW - Arteriovenous fistula

KW - Atorvastatin

KW - Primary failure

KW - Rosuvastatin

KW - Simvastatin

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84994504612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994504612&partnerID=8YFLogxK

U2 - 10.5301/jva.5000612

DO - 10.5301/jva.5000612

M3 - Article

C2 - 27768209

AN - SCOPUS:84994504612

VL - 17

SP - 471

EP - 476

JO - Journal of Vascular Access

JF - Journal of Vascular Access

SN - 1129-7298

IS - 6

ER -